News Search Results
Mar 31, 2026, 06:15 ET Epson Announces Authorized Distribution Alliance with Clayton Controls to Deliver Advanced Automation Solutions to the Southwest Region
of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For
More news about: Epson America, Inc.
Mar 31, 2026, 05:01 ET Deakin University advances global agenda for affordable health through RAAH Roundtable
participate in the kick-off roundtable.""We believe that the alliance will make sure that all the advances and development in AI, biotechnology and technology should be put to use for better health for everybody, such that we let go of social inequality in health."Welcoming
More news about: Deakin University
Mar 30, 2026, 15:49 ET ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
[email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Mar 30, 2026, 14:12 ET Texas Healthcare and Bioscience Institute Releases Strategic Vision to Advance the Texas Life Sciences Ecosystem
healthcare and bioscience industry, today released a comprehensive report outlining a strategic vision for strengthening Texas' life sciences and biotechnology ecosystem. "
More news about: Texas Healthcare and Bioscience Institute
Mar 30, 2026, 14:00 ET WesternU COMP celebrates 100% residency placement for third consecutive year
www.westernu.edu), located in Pomona, Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Mar 30, 2026, 13:00 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
(short video)UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 30, 2026, 12:34 ET Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society's 2026 Medal of Honor
BOSTON, March 30, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging diseases, announces that the
More news about: Skyhawk Therapeutics
Mar 30, 2026, 10:38 ET QuantiPath Appoints Industry Veteran Michael E. Strauss to Board of Directors
building a world-class leadership team and advancing innovation in food safety diagnostics.About QuantiPathQuantiPath is a biotechnology company revolutionizing food safety testing through precision genetic diagnostics. Its flagship product, GenoPATHx, is the only rapid test kit that
More news about: QuantiPath
Mar 30, 2026, 10:00 ET Sanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence
date, Sanyou has empowered over 1,200 new drug development projects and established solid partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide.Over the years, Sanyou has continuously increased R&D investment, optimized innovation framework, assembled top-tier
More news about: Sanyou Bio
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
ensuring its innovative platform technologies reached new heights.In 2025 alone, the Company established multiple collaborations with global biotechnology innovators and multinational pharmaceutical companies, including Windward Bio, AstraZeneca, Otsuka, Pfizer and Bristol Myers Squibb. Among these,
More news about: Harbour BioMed
Mar 30, 2026, 09:35 ET Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
health, and extend lives through the power of science and technology.About Braveheart BioBraveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science
More news about: Braveheart Bio
Mar 30, 2026, 09:05 ET Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department
More news about: Anixa Biosciences, Inc.
Mar 30, 2026, 09:05 ET Centivax Closes $37 Million Financing to Accelerate Phase 2 Clinical Development of Universal Flu and Advance Follow-On Portfolio to Clinical Readiness
SOUTH SAN FRANCISCO, Calif., March 30, 2026 /PRNewswire/ -- Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the closing of a $37
More news about: Centivax, Inc.
Mar 30, 2026, 09:00 ET Delonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104
SHANGHAI and PERTH, Australia, March 30, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced the initiation of first-in-human (FIH) dosing in a Phase 1 clinical
More news about: Delonix Bioworks
Mar 30, 2026, 09:00 ET Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche Diagnostics
Mar 30, 2026, 07:00 ET Matricelf Enters Strategic Collaboration with Japan's CiRA Foundation to Advance Next-Generation Regenerative Manufacturing
TEL AVIV, Israel and KYOTO, Japan, March 30, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing a novel autologous engineered neural tissue therapy for patients with spinal cord injury, today announced it has entered into
More news about: Matricelf Ltd.
Mar 30, 2026, 07:00 ET Nanoscope Therapeutics Receives Orphan Drug Designation in Saudi Arabia for MCO-010, Expands Global Regulatory Leadership in Vision Restoration
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Mar 29, 2026, 20:30 ET Insilico Medicine Announces Global R&D Collaboration with Lilly
Mass., March 29, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, today announced a drug discovery collaboration with Eli Lilly and Company
More news about: Insilico Medicine
Mar 28, 2026, 16:45 ET REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 28, 2026, 12:36 ET Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
diseases. It is wholly owned by Nektar Therapeutics.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Mar 28, 2026, 02:31 ET Aphranel Founder Invited by People's Daily to Discuss Long-Term Development in China's Medical Aesthetics Sector
SHANGHAI, March 28, 2026 /PRNewswire/ -- Lin Guangming, founder of Moyom Biotechnology and the Aphranel brand, was invited to participate in a policy-focused industry discussion on China's medical aesthetics sector during the country's
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Mar 27, 2026, 16:30 ET /C O R R E C T I O N -- Boqii Holding Limited/
[1] Net loss for the first half of fiscal 2026 excluded Nanjing Xingmu Biotechnology Co., Ltd. ("Nanjing Xingmu"), as the Company disposed the entity effective April 1, 2025(as described below). Net loss for the first half of fiscal
More news about: Boqii Holding Limited
Mar 27, 2026, 16:12 ET Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
March 27, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Mar 27, 2026, 14:52 ET IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
e-mail at [email protected] ALLEGATIONS: ImmunityBio is a biotechnology company that focuses on innovating, developing, and commercializing next-generation immunotherapies. According to the complaint, ImmunityBio's
More news about: Robbins Geller Rudman & Dowd LLP